Education
About Us
Working with TipRanks
Follow Us
Regen Biopharma (RGBP)
OTHER OTC:RGBP
Total Valuation
Regen Biopharma has a market cap or net worth of $155.36K. The enterprise value is $1.25M.
Market Cap$155.36K
Enterprise Value$1.25M
Share Statistics
Regen Biopharma has 129,468,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding129,468,580
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Regen Biopharma’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 6.19%.
Return on Equity (ROE)0.20
Return on Assets (ROA)-4.64
Return on Invested Capital (ROIC)6.19%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee236.56K
Profits Per Employee-1.27M
Employee Count1
Asset Turnover0.86
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Regen Biopharma is ―. Regen Biopharma’s PEG ratio is 0.00377.
PE Ratio―
PS Ratio1.34
PB Ratio-0.05
Price to Fair Value-0.05
Price to FCF-0.83
Price to Operating Cash Flow-0.23
PEG Ratio0.00377
Income Statement
In the last 12 months, Regen Biopharma had revenue of 236.56K and earned -1.27M in profits. Earnings per share was -0.05.
Revenue236.56K
Gross Profit236.56K
Operating Income-338.54K
Pretax Income-1.27M
Net Income-1.27M
EBITDA-338.54K
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -515.15K and capital expenditures 0.00, giving a free cash flow of -515.15K billion.
Operating Cash Flow-515.15K
Free Cash Flow-515.15K
Free Cash Flow per Share>-0.01
Dividends & Yields
Regen Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change-87.50%
50-Day Moving Average0.01
200-Day Moving Average0.04
Relative Strength Index (RSI)43.89
Average Volume (3m)586.57K
Important Dates
Regen Biopharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Regen Biopharma as a current ratio of 0.04, with Debt / Equity ratio of -18.44%
Current Ratio0.04
Quick Ratio0.04
Debt to Market Cap2.50
Net Debt to EBITDA-2.34
Interest Coverage Ratio-1.61
Taxes
In the past 12 months, Regen Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Regen Biopharma EV to EBITDA ratio is -3.28, with an EV/FCF ratio of -2.90.
EV to Sales4.69
EV to EBITDA-3.28
EV to Free Cash Flow-2.90
EV to Operating Cash Flow-2.90
Balance Sheet
Regen Biopharma has $4.58K in cash and marketable securities with $1.21M in debt, giving a net cash position of -$1.21M billion.
Cash & Marketable Securities$4.58K
Total Debt$1.21M
Net Cash-$1.21M
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.27
Margins
Gross margin is 100.00%, with operating margin of -143.11%, and net profit margin of -538.76%.
Gross Margin100.00%
Operating Margin-143.11%
Pretax Margin-538.76%
Net Profit Margin-538.76%
EBITDA Margin-143.11%
EBIT Margin-449.81%
Analyst Forecast
The average price target for Regen Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―